Dr Mathew Minardi
Global CDMO Sterling Pharma Solutions has appointed Dr Mathew Minardi as President US Operations.
The appointment follows Sterling’s acquisition of a facility in North Carolina from contract research and development specialist, CiVentiChem.
Based at the North Carolina site, Dr Minardi will head up Sterling’s North American operations. He brings with him a PhD in organic chemistry and a wealth of experience from previous roles at Accord Healthcare, Johnson and Johnson’s Noramco and Ampac Fine Chemicals.
“I’m delighted to join Sterling at a time of such rapid growth," said Dr Minardi.
"With 70% of our customer base already in North America, we have an ambitious vision for the company’s future in this market which started with building on our local presence. I’m excited to be on board to help facilitate Sterling’s continued growth.”
The acquisition of the CiVentiChem site is set to allow Sterling to enhance its chemistry development capabilities to support pre-clinical and early phase clinical supply.
Kevin Cook, Sterling Pharma Solutions CEO, said: “Mathew’s wealth of expertise in API development, his excellent leadership skills and his in-depth knowledge of CDMO customer requirements make him an invaluable new addition to the company.
“We are thrilled to have him join the team to spearhead our US arm as we work towards expanding the company’s presence in North America ensuring we can better service Sterling’s customer base in the area.”
Sterling Pharma Solutions was recently acquired by GHO Capital, a specialist healthcare investment firm based in London, UK. The management team at GHO is set to provide expert guidance as the company continues to expand its global presence.
A contract provider of small molecule API development and manufacturing services, Sterling Pharma Solutions caters to the global pharmaceutical industry.